Beacon Therapeutics Appoints Dr. Daniel Chung as Chief Medical Officer

LONDON and CAMBRIDGE, Mass.—Beacon Therapeutics Holdings Limited, a clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, has announced the appointment of Dr. Daniel Chung as chief medical officer, effective immediately. According to the announcement, Dr. Chung brings a wealth of experience in clinical ophthalmology, academic research and gene therapy development spanning three decades. Most recently, he served as chief medical officer at SparingVision, a clinical-stage genomic medicine company.